San­thera rene­go­ti­ates mile­stone pay­ment, in­creas­es liq­uid­i­ty run­way in­to 2023 pend­ing NDA fil­ing

Last year, Swiss biotech San­thera Phar­ma­ceu­ti­cals claimed a Phase IIb win for va­morolone for Duchenne — just a few months af­ter ax­ing its pre­vi­ous Duchenne can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER